

## 2020 Market Analysis of Annual Meeting on Cardiology and Heart Failure


John Bella

Senior Professor, Heart Failure and Cardiovascular, University of South Alabama Medical Center Division of Cardiology, Alabama, USA, E-mail: jhonbella2019@gmail.com

### Market Analysis


The heart failure market is set to upward jostle from round \$3.2 billion in 2015 to \$11.8 billion with the aid of 2025, representing a compound annual increase fee of 13.7%, in accordance to research and consulting association Global Data.

The company's present day report, Pharma Point: Heart Failure – Global Drug Forecast and Market Analysis to 2025, states that the key drivers of this sizable growth, which will occur throughout the seven fundamental markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be the launch of Novartis' first-in-class drug, Entresto, and several acute coronary heart failure add-on therapies, as properly as an amplify in the global incidence of persistent coronary heart failure.



Elizabeth Hamson, Ph.D., Global Data's Analyst covering Cardiovascular and Metabolic Disorders, explains: "Novartis' Entresto is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), which used to be launched in the US in 2015 and the five European international locations in 2016, and is set for release in Japan via 2020. The drug has raised the benchmark for efficacious persistent coronary heart failure therapy, though uptake has been slow. Entresto has struggled to penetrate the chronic heart failure market, accomplishing dismal income in the US considering the fact that its launch in July 2015. Global Data has recognized excessive pricing and the general reluctance of cardiologists and doctors to undertake new treatment options as the principal limitations to the uptake of this drug. Despite this, it is expected that Entresto will start to dominate the world coronary heart failure space, specifically after its label enlargement to heart failure with preserved ejection fraction, which is expected to take place in 2020, making it the strongest driver of market growth."

This document gives evaluation of the heart failure space across the seven predominant nations of the US, France, Germany, Italy, Spain, the UK, and Japan, together with annualized market statistics from 2015 and forecast to 2025. Key subjects included consist of strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the continual and acute coronary heart failure therapeutics arenas. It was constructed the use of information and facts sourced from proprietary databases, principal and secondary research, and in-house evaluation conducted through Global Data's group of enterprise experts.



### Importance & Scope:

- Guidelines into Practice sessions: learn how to use and understand the latest ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- Presentation of the latest updates in the field
- Learn from experts in more than 120 scientific sessions
- Make contacts in your profession among the 6'000 delegates expected
- Meet fellow researchers : we receive more than 150 abstracts and clinical cases
- Interact with the 300 expert faculties from around the world and ask all of your questions.
- Access institutional and industrial partners in the Exhibition

#### Target Audience:

This continuing medical education program is designed to meet the educational needs of cardiologists, cardiothoracic surgeons, family practice, internal medicine, hospitalists, advanced practice nurses, registered nurses, physician assistants, pharmacists, cardiology and cardiac surgery fellows and residents in training involved in the diagnosis and management of adult patients with heart failure or at risk for heart failure.

#### Related Companies/Industries:

- Sanofi
- Bayer AG
- Bristol-Myers Squibb Co
- Daiichi Sankyo Co Ltd
- Johnson & Johnson

**Related Associations and Societies:**

USA: The American Society for Preventive Cardiology; American Society of Nuclear Cardiology; American Heart Association; ACC; Cardiology Conferences 2020; American Stroke Association; Society for Cardiovascular Angiography and Interventions; Arizona Society of Echocardiography; Brazilian Society of Cardiology; World Cardiology Conferences 2020; Heart Failure Society of America; Canadian Association of

Cardiovascular Prevention and Rehabilitation; Clinical Cardiology Conferences 2020; Elsevier Society Partners in Cardiology; Heart Conferences 2020; American Society for Preventive Cardiology; American Society of Echocardiography; Heart Congress 2020; American Society of Hypertension; Brazilian Society of Hypertension; Cardiology Conferences 2020; Canadian Cardiovascular Society; Argentine Society of Cardiology; Cardiology Conferences 2020; Canadian Association of Interventional Cardiology; World Cardiology Conferences 2020; Congenital Cardiac Anesthesia Society; Cardiology Congress 2020; The American Association of Cardiovascular and Pulmonary Rehabilitation; Cardiovascular Congress 2020; Vascular and Endovascular Surgery Society.